In the year 2012 the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) proposed that the diagnosis of CeD may definitely be established in patients with compatible symptoms having anti-transglutaminase 2 (TG2) IgA levels 10 times above the cut-off value, followed by positive IgA EmA in a second blood sample, and carrying HLA-DQ2 and/or DQ8, avoiding the requirement of the intestinal biopsy (6). Here, CD79A is linked to cranioectodermal dysplasia.